Alliances
AbbVie and Harvard University entered into a $30 million collaborative research alliance to develop therapies against emergent viral infections, with a focus on those caused by coronaviruses and by viruses that lead to hemorrhagic fever.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 26, 2020.
Under terms of the licensing deal, Morphic will receive an infusion of $20 million for the license fee along with potential future development milestone payments and royalties from the sales of any commercialized candidates.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 24, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 21, 2020.
Regeneron will distribute REGN-COV-2 in the U.S. and Roche will handle distribution outside the U.S.
Eli Lilly will aim a checkpoint inhibitor it co-developed for the Chinese market at the United States and other western markets.
Together the two companies will scour comprehensive medical and molecular data sets of thousands of chronic kidney disease patients to identify and then develop possible drugs.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 19, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 17, 2020.
PRESS RELEASES